On June 3, 2021 Foresight Diagnostics, a privately-held cancer diagnostic company, reported that two abstracts that report the clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) and non-small cell lung cancer (NSCLC) were chosen for presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on June 4-8, 2021 (Press release, Foresight Diagnostics, JUN 3, 2021, View Source [SID1234583489]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The posters demonstrate the utility of Foresight Diagnostics proprietary PhasED-Seq technology to improve MRD detection rates in low disease burden settings in DLBCL and NSCLC patients.
Details of the posters to be presented:
Abstract 7565: Phased variants improve DLBCL minimal residual disease detection at the end of therapy
Detection of circulating tumor DNA (ctDNA) has prognostic value in DLBCL and could facilitate minimal residual disease (MRD) driven approaches. ctDNA detection has potential to change management of DLBCL in the clinic, however detection is still challenging in low-disease burden states (i.e., detection of MRD at the end of therapy). It is shown that phased variants (PVs) are common in B-cell lymphomas and occur in stereotyped locations, enabling an ‘off-the-shelf’ approach that does not require tumor tissue or patient-specific customization. PhasED-Seq (Phased Variant Enrichment & Detection Sequencing) can identify and track PVs for improved ctDNA MRD detection down to parts-per-million levels. The PhasED-Seq technology improves MRD detection compared to SNV-based methods at interim and end-of-treatment time-points for DLBCL.
Abstract 8518: Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer
The sensitivity of existing MRD methods that track single nucleotide variants (SNVs) is suboptimal due to the background error rates of SNVs. Phased variants (PVs) have a lower background error-rate than SNVs resulting in improved ctDNA MRD detection rates. PhasED-Seq was developed and applied to detect low-burden MRD in localized-stage lung cancer. PhasED-Seq improves MRD detection rates in lung cancer patients with low disease burden while maintaining high specificity. Phased variants were found to be common in most tumor types and can be applied to other cancers.
Due to the virtual nature of the annual meeting, pre-recorded presentations of each poster will be released for on-demand viewing on June 4, 2021 at 9:00 AM (EDT).
"We are pleased to present this compelling data on the PhasED-Seq technology at ASCO (Free ASCO Whitepaper) this year," says David Kurtz (MD/PhD), a Stanford University professor and co-founder of Foresight Diagnostics who will present the abstracts. "We show that PhasED-Seq more accurately distinguishes between patients who were cured and patients in need of additional therapy following curative intent treatment. This improved sensitivity for MRD detection in low-disease-burden settings will pave the way for adapted approaches to personalized therapy and novel clinical trial designs."
Learn more about attending the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting at View Source